These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29970440)

  • 1. Mechanisms of Resistance in Clinical Isolates of
    Liu L; Yu J; Tang M; Liu J
    Ann Clin Lab Sci; 2018 May; 48(3):355-362. PubMed ID: 29970440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
    Pérez A; Canle D; Latasa C; Poza M; Beceiro A; Tomás Mdel M; Fernández A; Mallo S; Pérez S; Molina F; Villanueva R; Lasa I; Bou G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3247-53. PubMed ID: 17638702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. soxRS induces colistin hetero-resistance in Enterobacter asburiae and Enterobacter cloacae by regulating the acrAB-tolC efflux pump.
    Telke AA; Olaitan AO; Morand S; Rolain JM
    J Antimicrob Chemother; 2017 Oct; 72(10):2715-2721. PubMed ID: 29091215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative genomics of Enterobacter cloacae complex before and after acquired clinical resistance to Ceftazidime-Avibactam.
    Senchyna F; Tamburini FB; Murugesan K; Watz N; Bhatt AS; Banaei N
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115511. PubMed ID: 34418822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the AcrAB-TolC efflux pump in the resistance, fitness, and virulence of Enterobacter cloacae.
    Pérez A; Poza M; Fernández A; Fernández Mdel C; Mallo S; Merino M; Rumbo-Feal S; Cabral MP; Bou G
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2084-90. PubMed ID: 22290971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of transcriptional activators SoxS, RobA, and RamA on expression of multidrug efflux pump AcrAB-TolC in Enterobacter cloacae.
    Pérez A; Poza M; Aranda J; Latasa C; Medrano FJ; Tomás M; Romero A; Lasa I; Bou G
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6256-66. PubMed ID: 23006750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.
    Veleba M; De Majumdar S; Hornsey M; Woodford N; Schneiders T
    J Antimicrob Chemother; 2013 May; 68(5):1011-8. PubMed ID: 23349441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHV-12 extended spectrum beta-lactamase associated with high-level ceftazidime resistance in Enterobacter cloacae isolated from Thailand.
    Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S; Niumsup PR
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):148-54. PubMed ID: 19323047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.
    Keeney D; Ruzin A; Bradford PA
    Microb Drug Resist; 2007; 13(1):1-6. PubMed ID: 17536927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment.
    Hornsey M; Ellington MJ; Doumith M; Scott G; Livermore DM; Woodford N
    Int J Antimicrob Agents; 2010 May; 35(5):478-81. PubMed ID: 20189357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
    Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
    Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
    Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae.
    Kaneko K; Okamoto R; Nakano R; Kawakami S; Inoue M
    J Clin Microbiol; 2005 Jun; 43(6):2955-8. PubMed ID: 15956430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activity and mechanism of action of ceftazidime and apigenin combination against ceftazidime-resistant Enterobacter cloacae.
    Eumkeb G; Chukrathok S
    Phytomedicine; 2013 Feb; 20(3-4):262-9. PubMed ID: 23218402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.
    Mimoz O; Jacolot A; Leotard S; Hidri N; Samii K; Nordmann P; Petitjean O
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3304-8. PubMed ID: 9835534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
    Shields RK; Iovleva A; Kline EG; Kawai A; McElheny CL; Doi Y
    Clin Infect Dis; 2020 Dec; 71(10):2713-2716. PubMed ID: 32236408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased quinolone susceptibility in high percentage of Enterobacter cloacae clinical isolates caused only by Qnr determinants.
    Zhao X; Xu X; Zhu D; Ye X; Wang M
    Diagn Microbiol Infect Dis; 2010 May; 67(1):110-3. PubMed ID: 20227223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Resistance to cefepime in Enterobacter cloacae isolates from hospitals in Bogotá, Colombia].
    González-Mejía EB; Valenzuela EM; Mantilla-Anaya JR; Leal-Castro AL; Saavedra-Trujillo CH; Eslava-Schmalbach J; Sierra-Rodriguez P
    Rev Salud Publica (Bogota); 2006; 8(2):191-9. PubMed ID: 17191603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?
    Menegucci TC; Bastos MS; Viana GF; Moreira RRB; Garcia LB; Cardoso CL; Tognim MCB
    J Chemother; 2017 Jun; 29(3):189-194. PubMed ID: 27077929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
    Hilty M; Sendi P; Seiffert SN; Droz S; Perreten V; Hujer AM; Bonomo RA; Mühlemann K; Endimiani A
    Int J Antimicrob Agents; 2013 Mar; 41(3):236-49. PubMed ID: 23313399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.